NSNadezhda A. Snegireva

Nadezhda A. Snegireva

*This is an algorithmically generated author record based on publicly available information.

Nadezhda A. Snegireva has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The adoptive transfer of regulatory B lymphocytes prevents severe damage to lung tissues during respiratory infection with the influenza A/H1N1 virus

    by Ilya N. Dyakov, Irina N. Chernyshova, Marina V. Gavrilova, Kristina K. Bushkova, Artyom A. Rtishchev, Natalia E. Abayeva, Stanislav G. Markushin, Dmitry A. Khochenkov, Irina D. Bulgakova, Nadezhda A. Snegireva, et al.

    The aim of the study is to investigate the role of regulatory B lymphocytes in the regulation of the inflammatory process in the lungs against the background of influenza virus infection (A/H1N1/WSN/1933). Materials and methods. On the day after intranasal infection with influenza A/H1N1/WSN/1933 virus, CBA/N mice received intravenous B cells from CBA mice: Breg (induced in vitro by activators, high content of IL-10+ regulatory B cells), Bcontr (incubated in vitro without activators, IL-10 content+ minimal regulatory B cells), BPerC (isolated abdominal B cells, without in vitro incubation). On the 4th day after infection, histological changes in the lungs, the number of IgM and IgG antibody producers in the lungs and spleen, as well as the viral load in the lungs were evaluated. Results. Intranasal infection of CBA/N mice with influenza A/H1N1/WSN/1933 virus was accompanied by pronounced morphological changes in lung tissue detected on day 4, including tissue structural disorders and cellular infiltration. The adoptive transfer of Breg the day after infection was associated with a decrease in the severity of histological signs of lung damage compared with the group without transfer. The transfer of Bcontr and BPerC was also accompanied by a decrease in the detected tissue damage, but the effect was less pronounced than with Breg transfer. In all groups with CBA B cell transfer, there was an increase in the number of IgM and IgG antibody producers in the spleen and lungs. At the same time, there were no differences in the indicator of viral load in the lungs between the compared groups. Conclusion. The revealed prevention of severe lung tissue damage in CBA/N mice infected with influenza A/H1N1/WSN/1933 virus during the adoptive transfer of in vitro-induced regulatory B cells from CBA mice is attributable to a combination of increased immune response due to the transferred cells and the regulatory activity of IL-10+ regulatory B cells.

  • Open Access

    Immunogenicity of GamLPV, an intranasal live vaccine for pertussis prevention, in adult volunteers: a blind, randomised, placebo-controlled trial to optimise the method and schedule of administration

    by A. A. Lidzhieva, A. Yu. Medkova, S. V. Kulikov, L. N. Sinyashina, R. A. Sioundioukova, I. N. Chernyshova, M. V. Gavrilova, K. K. Bushkova, N. A. Snegireva, I. N. Dyakov, et al.

    INTRODUCTION. Currently used inactivated vaccines with acellular/whole-cell pertussis components do not provide sterilising or sufficiently long-lasting immunity, nor do these vaccines prevent the spread of the pathogen or infection. A live pertussis vaccine for intranasal administration, GamLPV, has passed the necessary preclinical studies and a clinical trial that established the optimal dose for single-dose vaccination.AIM. This study aimed to optimise the method and schedule of administration of the GamLPV intranasal live vaccine for pertussis prevention on the basis of the immunogenicity results obtained in a clinical trial involving healthy volunteers aged 18 to 40 years.MATERIALS AND METHODS. This blind, randomised, placebo-controlled clinical trial enrolled 50 healthy adults, who were then randomised into two groups according to the method of GamLPV administration (drops or spray). The study evaluated the efficacy of two administration schedules, including single-dose vaccination and double-dose vaccination with an interval of 60 days. The study analysed nasopharyngeal and oropharyngeal aspirates, serum samples, and peripheral blood mononuclear cells from volunteers. The levels of IgM, IgA, and IgG antibodies specific to Bordetella pertussis and the levels of secretory IgA antibodies were measured in serum samples and nasal aspirates, respectively, by enzyme-linked immunosorbent assay. Agglutinating antibody titres were determined by agglutination tests. The quantitative determination of B. pertussis DNA in aspirates used real-time polymerase chain reaction. Cell-mediated immune responses were assessed by the production of IFN-γ and IL-17 cytokines in peripheral blood mononuclear cells.RESULTS. GamLPV administration to volunteers induced B. pertussis-specific IgG and IgA antibodies observed in serum samples, secretory IgA antibodies identified in aspirates, and increased titres of total antibodies to B. pertussis measured by agglutination tests, regardless of the vaccination schedule and the method of administration. Repeated GamLPV administration had a pronounced booster effect, as evidenced by elevated titres of antibodies of all classes from day 14. Moreover, repeated vaccination reduced the time for clearance of B. pertussis bacteria compared with that after the first vaccination (from 28 to 14 days). There were no significant differences in the time courses and values of the measured parameters for nasal vaccine delivery by spray and drops.CONCLUSIONS. Intranasal vaccination with GamLPV induces pronounced humoral and cellular immune responses and nasal mucosal immunity against pertussis infection in adults. The recommended method for GamLPV administration is nasal drops. The accelerated clearance of bacteria observed after the second vaccination is indicative of sterilising immunity provided by the first vaccination, which can ultimately reduce pertussis transmission in the population.


  • Open Access

    The content of regulatory B-lymphocytes in autoimmune adrenal insufficiency

    by E. A. Troshina, N. F. Nuralieva, I. N. Dyakov, M. Yu. Yukina, M. V. Gavrilova, I. N. Chernyshova, N. A. Snegireva, O. A. Svitich, I. I. Dedov, М. Ю. Юкина

    Introduction: Currently, the need to expand knowledge about the mechanisms of impaired immune tolerance in autoimmune adrenal insufficiency (AAI) remains relevant. It is not excluded that in AAI there are disturbances in the system of regulatory B-lymphocytes (Breg).Objective: To assess the state of the B-regulatory cells system of immunity in AAI.Material and methods: the content of Breg was evaluated in patients with AAI, including isolated AAI and AAI as part of autoimmune polyglandular syndrome type 2 (APS-2) and as part of APS-1, in patients with primary adrenal insufficiency (1-AI) of non-autoimmune genesis, conditionally healthy individuals without AI and autoimmune diseases.Results: A decrease in the content of Breg in vivo was revealed in patients with isolated AAI and AAI in the composition of APS-2 compared with conditionally healthy participants. The content of Breg in vivo in patients with 1-AI of non-autoimmune genesis did not statistically differ from the indicators of conditionally healthy participants.Conclusion: for the first time in the world, a tendency to a decrease in the content of Breg in AAI, caused by a disturbance of peripheral immune tolerance, was found. Thus, these cells can be considered as promising markers for the prognosis, early diagnosis, and differential diagnosis of AAI.

  • Open Access

    Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers

    by G. I. Karataev, A. Yu. Medkova, E. G. Semin, L. N. Sinyashina, R. A. Sioundioukova, S. V. Kulikov, N. A. Snegireva, I. N. Chernishova, M. V. Gavrilova, K. K. Bushkova, et al.

    Introduction. The increase in the incidence of whooping cough in children and adults of different age groups justifies the need for their revaccination and the development of new, acceptable for these purposes. This work is devoted to substantiating the design of a clinical trial and describing the results of a comparative study of the safety and tolerability of the drug "GamLPV" with two-fold intranasal administration to healthy adult volunteers using two methods. The choice of the scheme and method of administration of the drug is justified. The serological structure of the population of adults aged 18–40 years living in Moscow and the Moscow region is characterized.Aim. Determination of the safety and tolerability of the drug with a double intranasal administration of the vaccine by drip method and spraying through an actuator.Materials and methods. A randomized placebo-controlled trial included 50 healthy male and female volunteers aged 18 to 40 years who met the inclusion criteria. The volunteers were divided into 2 groups of 25 people: a drip method of administration and spraying through an "actuator". By both methods, the drug was administered twice with an interval of 60 days.Results and discussion. Serological analysis of the population of healthy volunteers at the prescreening stage justified the inclusion in the study of volunteers containing anti-pertussis antibodies in the blood (IgG ≤40 Ed/ml). A comparison of the results of preclinical studies on an experimental model of non-human monkeys and the first phase of a clinical study of GamLPV allowed us to propose two methods of double administration of the drug as a promising vaccination scheme for volunteers. A comparative randomized study shows the safety of using the proposed scheme for vaccination of adult volunteers.Conclusions. Both proposed methods of double administration can be used to plan a multicenter study to research the immunogenicity and protective activity of GamLPV.


  • Open Access

    Immunogenicity of the drug "Live intranasal vaccine for the prevention of pertussis" (GamLPV) with a single use in healthy volunteers

    by A. Yu. Medkova, A. A. Lidzhiyeva, E. G. Semin, L. N. Sinyashina, R. A. Syundyukova, N. A. Snegireva, I. N. Chernyshova, M. V. Gavrilova, K. K. Bushkova, L. V. Kolobukhina, et al.

    Introduction. A significant increase in the incidence of pertussis in the world, including among adolescents and adults, the prevalence of mild forms of the disease and asymptomatic carrier of bacteria B. pertussis, and the resulting need for mass revaccination of different age groups determine the demand for new vaccines against B. pertussis. In N.F. Gamaleya Federal Research Center for Epidemiology and Microbiology, a live intranasal pertussis vaccine for the prevention of pertussis (GamLPV) has been developed. The GamLPV vaccine underwent preclinical studies that proved its safety and effectiveness in experiments on small laboratory animals and nonhuman monkeys. Safety of vaccine is shown in clinical studies on healthy volunteers.The aim of the study is to assess the immunogenicity of different doses of the drug GamLPV when first used in healthy volunteers.Materials and methods. The study was conducted as randomized placebo-controlled, blind trial with consistent volunteer inclusion and dose escalation. Study ID in clinicaltrials.gov database: NCT03137927 (A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine). The following parameters of humoral and cellular immune responses were assessed in dynamics: levels of specific IgM, IgG and IgA antibodies in blood serum of volunteers and the number of cytokines interleukin-17, tumor necrosis factor-α, interferon-γ produced after specific induction in vitro of blood mononuclears of vaccinated volunteers. Dynamics of attenuated bacteria persistence in nasopharynx of vaccinated volunteers was evaluated.Results. Intranasal vaccination of volunteers with the drug Gam LPV resulted in the formation of a specific humoral (IgG and IgA) and cellular immune response. The dose-dependent nature of immunoglobulin and cytokine production was shown. Attenuated bacteria persisted for a long time in the nose/oropharynx of vaccinated volunteers.Discussion. Good tolerability of all tested doses of the drug justifies the choice for further investigation of a vaccine dose equal to 4 × 109 CFU. At the next stage, the safety and immunogenicity of two-time vaccination of volunteers will be studied.


  • Open Access

    IgM- and IgA-response of peritoneal B-1 cells to the TI-2 antigen with the presence of γδT cells in vitro

    by N. A. Snegireva, E. V. Sidorova, I. N. Dyakov, M. V. Gavrilova, I. N. Chernyshova, E. P. Pashkov, O. A. Svitich

    IgA is an important component of the mucosal system of the body. It limits penetration of pathogens into the bloodstream. Inflammatory diseases such as Crohn disease and colitis may be associated with disorders of IgA synthesis. Both B1 and B2 cells are a source of IgA in the intestines. Special attention is paid to B1 cells, which are able to respond to T-independent type 2 antigens and produce natural antibodies. B1 cells produce about 50% of the intestinal IgA including specific antibodies to the components of microorganisms contained in the gastrointestinal tract. The mechanism of IgA formation in the T-independent way is not investigated in details. It was suggested that the γδТ-cells promote switching to IgA synthesis by B1 cells. This assumption may be supported by their co-localization with B1 lymphocytes in the intestinal mucosa, as well as participation, along with B1 cells, in formation of the first-line defense against the pathogens. In addition, the both lymphocyte subpopulations evolve during initial ontogenesis, earlier than “classic” В2 and αβT cells. Therefore, it was suggested that γδT lymphocytes may be involved into the processes of induction and/or regulation of IgM and IgA production by B1 cells in response to TH2 antigens.In the present study, we have shown the effect of γδT cells upon generation of IgM- and IgA-forming B1 cells in response to α-1,3-dextran in vitro. We also studied the dynamics of the mRNA expression for IgM- and IgA-heavy chains by the B1 cells at different terms of in vitro culture.It was found that, during co-cultivation of B1 cells with 20% γδT lymphocytes, there is no increase in the number of dextran-specific IgM-producing cells. The B1 cells exhibited an increase of IgM heavy chain mRNA expression in response to dextran but not in co-cultures. Expression of mRNA for IgM heavy chains in co-cultures was decreased compared to non-treated B-cell cultures. Contrary to the earlier assumption, a presence of γδT lymphocytes in culture did not enhance the formation of IgA producents. The obtained data suggest regulatory properties of the γδТ lymphocytes during the B1 cells response to T-independent antigens.


  • Open Access

    INFLUENCE OF Breg AND IL-10 UPON HUMORAL IMMUNE RESPONSE

    by M. V. Gavrilova, N. A. Snegireva, E. V. Sidorova

    ВЛИЯНИЕ Breg И IL-10 НА ГУМОРАЛЬНЫЙ ИММУННЫЙ ОТВЕТ